The U.S. Food and Drug Administration announced the availability of a draft guidance aimed at increasing the amount of safety information the agency has about the dietary supplement marketplace by providing the industry an opportunity to submit late new dietary ingredient (NDI) notifications.
GlaxoSmithKline said on April 6 the company’s consumer arm stopped shipments of supplements and vitamins to Russia as a result of Moscow’s invasion of Ukraine and would prioritize the supply of over-the-counter medicines for basic needs.
In this webinar, you will hear from the Kline Group about a trend moving into dietary supplements, and from Catalent about how supplement brands are accelerating toward a more natural, plant–based portfolio, including in the ever–important heart health market.
Shares of Amarin Corporation were down more than 70 percent in trading after a judge ruled that generic companies can go ahead and seek approval of generic versions of the drug manufacturer’s heart disease drug Vascepa.
The U.S. Food and Drug Administration rebuked 17 companies against selling unapproved products which claim to treat Alzheimer’s disease and other serious ailments.
Clinical data for a fish-oil-based drug from Amarin Corporation confirmed the drug’s ability to reduce the relative risk reduction of adverse cardiovascular events by 25 percent, including a 20 percent reduction in cardiovascular death.
Today, the U.S. Food and Drug Administration took an important step to better protect consumers from the dangers of highly concentrated and pure caffeine products. These products present a significant public health threat because of the high risk that they will be erroneously used at excessive, potentially dangerous doses. Highly concentrated and pure caffeine, often sold in bulk packages, have been linked to at least two deaths in otherwise healthy individuals.
Industry insiders say Johnson & Johnson is no longer interested in Pfizer’s $20 billion consumer healthcare business
The U.S. Food and Drug Administration is advising consumers and health-care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
Oral glucosamine – a natural supplement often marketed for joint pain – has no more effect than a dummy pill, according to a new review of available research.